دورية أكاديمية
أعرض في EDS

Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study.

التفاصيل البيبلوغرافية
العنوان: Downfalls of Chemical Probes Acting at the Kinase ATP-Site: CK2 as a Case Study.
المؤلفون: Atkinson EL; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK., Iegre J; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK., Brear PD; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK., Zhabina EA; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK., Hyvönen M; Department of Biochemistry, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK., Spring DR; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2021 Mar 31; Vol. 26 (7). Date of Electronic Publication: 2021 Mar 31.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: Casein Kinase II/*metabolism , Molecular Probes/*chemistry , Protein Kinase Inhibitors/*chemistry , Protein Kinases/*chemistry , Protein Kinases/*metabolism, Adenosine Triphosphate/metabolism ; Binding Sites ; COVID-19 ; Casein Kinase II/chemistry ; Dichlororibofuranosylbenzimidazole/chemistry ; Dichlororibofuranosylbenzimidazole/pharmacology ; Humans ; Molecular Probes/metabolism ; Naphthyridines/chemistry ; Naphthyridines/pharmacology ; Phenazines/chemistry ; Phenazines/pharmacology ; Polyphenols/chemistry ; Polyphenols/pharmacology ; Protein Kinase Inhibitors/pharmacology
مستخلص: Protein kinases are a large class of enzymes with numerous biological roles and many have been implicated in a vast array of diseases, including cancer and the novel coronavirus infection COVID-19. Thus, the development of chemical probes to selectively target each kinase is of great interest. Inhibition of protein kinases with ATP-competitive inhibitors has historically been the most widely used method. However, due to the highly conserved structures of ATP-sites, the identification of truly selective chemical probes is challenging. In this review, we use the Ser/Thr kinase CK2 as an example to highlight the historical challenges in effective and selective chemical probe development, alongside recent advances in the field and alternative strategies aiming to overcome these problems. The methods utilised for CK2 can be applied to an array of protein kinases to aid in the discovery of chemical probes to further understand each kinase's biology, with wide-reaching implications for drug development.
References: Planta Med. 1999 Feb;65(1):9-13. (PMID: 10083837)
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):200-9. (PMID: 16172032)
Bioorg Med Chem Lett. 2007 Aug 1;17(15):4191-5. (PMID: 17540560)
J Mol Biol. 2007 Jul 13;370(3):427-38. (PMID: 17524418)
Cell Mol Life Sci. 2009 Jun;66(11-12):1858-67. (PMID: 19387548)
Bioorg Chem. 2011 Dec;39(5-6):192-210. (PMID: 21872901)
Eur J Med Chem. 2020 Jun 1;195:112267. (PMID: 32283296)
FASEB J. 1995 May;9(8):576-96. (PMID: 7768349)
FEBS Lett. 1995 Aug 1;369(1):57-61. (PMID: 7641885)
J Med Chem. 2004 Dec 2;47(25):6239-47. (PMID: 15566294)
Science. 2002 Dec 6;298(5600):1912-34. (PMID: 12471243)
Cancer Res. 2010 Dec 15;70(24):10288-98. (PMID: 21159648)
J Med Chem. 2010 Apr 8;53(7):2719-40. (PMID: 20131845)
Biochem J. 2009 Jul 15;421(3):387-95. (PMID: 19432557)
Expert Rev Clin Pharmacol. 2020 Jan;13(1):1-6. (PMID: 31810398)
ACS Med Chem Lett. 2020 Apr 07;11(5):713-719. (PMID: 32435375)
Cell Mol Life Sci. 2014 Aug;71(16):3173-85. (PMID: 24442476)
Bioorg Med Chem Lett. 2011 Mar 15;21(6):1687-91. (PMID: 21316963)
ACS Chem Biol. 2013 May 17;8(5):1044-52. (PMID: 23534475)
J Nat Prod. 1992 May;55(5):696-8. (PMID: 1517743)
Cell Rep. 2017 Mar 28;18(13):3155-3166. (PMID: 28355567)
Org Biomol Chem. 2021 May 26;19(20):4380-4396. (PMID: 34037044)
Expert Rev Anticancer Ther. 2018 Dec;18(12):1249-1270. (PMID: 30259761)
Annu Rev Biochem. 2012;81:587-613. (PMID: 22482904)
Med Res Rev. 2010 May;30(3):419-62. (PMID: 19526464)
Mol Biosyst. 2008 Sep;4(9):889-94. (PMID: 18704226)
J Med Chem. 2007 Feb 8;50(3):409-24. (PMID: 17266192)
Bioinformatics. 2010 Jan 15;26(2):198-204. (PMID: 19942586)
Chem Sci. 2016 Nov 1;7(11):6839-6845. (PMID: 28451126)
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15046-52. (PMID: 21852571)
Bioorg Med Chem Lett. 2008 Jan 15;18(2):619-23. (PMID: 18055206)
EMBO Rep. 2008 Aug;9(8):795-801. (PMID: 18583988)
J Nat Prod. 2016 Mar 25;79(3):616-28. (PMID: 26900761)
Clin Cancer Res. 2007 Feb 1;13(3):1019-28. (PMID: 17289898)
Biochemistry. 2011 Oct 4;50(39):8478-88. (PMID: 21870818)
Biochim Biophys Acta. 2013 Jul;1834(7):1402-9. (PMID: 23360763)
Mol Cell Biochem. 2011 Oct;356(1-2):67-73. (PMID: 21739155)
Biochem Biophys Res Commun. 2020 Oct 20;531(3):409-415. (PMID: 32800562)
Bioorg Chem. 2020 Sep;102:104062. (PMID: 32683178)
Sci Adv. 2019 Jan 23;5(1):eaau9060. (PMID: 30746467)
Dis Model Mech. 2016 Aug 1;9(8):839-48. (PMID: 27483355)
ACS Omega. 2020 Oct 05;5(41):26720-26731. (PMID: 33110998)
Biochem J. 2007 Dec 15;408(3):297-315. (PMID: 17850214)
J Biol Chem. 1986 Mar 5;261(7):3414-9. (PMID: 3456346)
Molecules. 2018 Apr 15;23(4):. (PMID: 29662024)
Nat Rev Drug Discov. 2011 Jun 24;10(7):507-19. (PMID: 21701501)
Q Rev Biophys. 2009 Feb;42(1):1-40. (PMID: 19296866)
ACS Med Chem Lett. 2012 Jan 24;3(4):278-83. (PMID: 24900464)
N Engl J Med. 2019 Jul 25;381(4):338-348. (PMID: 31340094)
J Med Chem. 2003 Jun 19;46(13):2656-62. (PMID: 12801229)
Org Biomol Chem. 2012 Nov 21;10(43):8645-53. (PMID: 23032938)
Biochem Biophys Res Commun. 1995 Mar 8;208(1):418-24. (PMID: 7887958)
Molecules. 2020 Jul 15;25(14):. (PMID: 32679723)
Oncogene. 1998 Jun 4;16(22):2855-63. (PMID: 9671406)
Cancer Res. 1994 Apr 15;54(8):2262-8. (PMID: 7513612)
Oncogene. 2017 Aug 24;36(34):4943-4950. (PMID: 28436950)
Chem Rev. 2001 Aug;101(8):2209-42. (PMID: 11749371)
Biochem J. 2003 Sep 15;374(Pt 3):639-46. (PMID: 12816539)
Int J Mol Sci. 2019 Jun 06;20(11):. (PMID: 31174387)
Oncogenesis. 2017 Jan 30;6(1):e293. (PMID: 28134934)
Oncotarget. 2016 Aug 16;7(33):53191-53203. (PMID: 27448963)
J Med Chem. 2019 Feb 28;62(4):1817-1836. (PMID: 30689946)
Bioorg Chem. 2020 Mar;96:103608. (PMID: 32058103)
Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):10145-50. (PMID: 27555590)
Cancer Discov. 2019 Oct;9(10):OF2. (PMID: 31471291)
J Med Chem. 2019 Feb 28;62(4):1803-1816. (PMID: 30689953)
Biochem Biophys Res Commun. 1986 Mar 13;135(2):397-402. (PMID: 3457562)
FEBS Lett. 2001 May 4;496(1):44-8. (PMID: 11343704)
Drugs. 2019 Oct;79(15):1719-1725. (PMID: 31571162)
Biochim Biophys Acta. 2010 Mar;1804(3):499-504. (PMID: 19665589)
J Med Chem. 2011 Jan 27;54(2):635-54. (PMID: 21174434)
Cell. 2020 Aug 6;182(3):685-712.e19. (PMID: 32645325)
J Exp Med. 1954 Mar;99(3):227-50. (PMID: 13130796)
J Biol Chem. 2002 Jun 21;277(25):22509-14. (PMID: 11956194)
EMBO J. 1998 May 1;17(9):2451-62. (PMID: 9564028)
J Med Chem. 2020 Nov 12;63(21):12786-12798. (PMID: 33119282)
ACS Med Chem Lett. 2016 Jan 20;7(3):300-5. (PMID: 26985319)
Biochemistry. 2004 Oct 12;43(40):12931-6. (PMID: 15461466)
J Med Chem. 2016 Apr 14;59(7):3392-408. (PMID: 27003761)
Nat Biotechnol. 2008 Jan;26(1):127-32. (PMID: 18183025)
Chem Biol. 2008 Feb;15(2):111-7. (PMID: 18291315)
Nat Rev Cancer. 2009 Jan;9(1):28-39. (PMID: 19104514)
Molecules. 2020 Mar 25;25(7):. (PMID: 32218358)
Cell Mol Life Sci. 2009 Jun;66(11-12):1830-9. (PMID: 19387551)
Curr Med Chem. 2013;20(5):671-93. (PMID: 23210774)
Bioorg Med Chem. 2018 Jul 15;26(11):3016-3020. (PMID: 29759799)
Nature. 2000 Sep 21;407(6802):395-401. (PMID: 11014197)
Biochem J. 2000 Oct 1;351(Pt 1):95-105. (PMID: 10998351)
Leukemia. 2007 Jan;21(1):178-80. (PMID: 17082777)
Cell. 2002 May 3;109(3):275-82. (PMID: 12015977)
Eur J Biochem. 1990 Jan 12;187(1):89-94. (PMID: 2105215)
Bioinformatics. 2008 Aug 15;24(16):i14-20. (PMID: 18689816)
Bioorg Med Chem. 2017 Apr 1;25(7):2277-2284. (PMID: 28274673)
Bioorg Med Chem. 2003 Sep 1;11(18):3997-4002. (PMID: 12927861)
PLoS One. 2014 Apr 17;9(4):e94978. (PMID: 24743259)
Bioorg Chem. 2018 Oct;80:266-275. (PMID: 29966873)
J Cell Sci. 2002 Oct 15;115(Pt 20):3873-8. (PMID: 12244125)
Mol Pharmacol. 2015 Aug;88(2):316-25. (PMID: 25993998)
Drugs. 2019 Nov;79(16):1805-1812. (PMID: 31602563)
Cell Chem Biol. 2021 Apr 15;28(4):546-558.e10. (PMID: 33484635)
Biochem Biophys Res Commun. 2003 Jun 20;306(1):129-33. (PMID: 12788077)
Nature. 2001 Feb 15;409(6822):860-921. (PMID: 11237011)
Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92. (PMID: 21982499)
ChemMedChem. 2010 Jan;5(1):23-34. (PMID: 19774589)
Biochem Biophys Res Commun. 2020 Jan 15;521(3):753-761. (PMID: 31703842)
Bioconjug Chem. 2015 Dec 16;26(12):2324-35. (PMID: 26559659)
Immunol Res. 2015 May;62(1):35-45. (PMID: 25752455)
J Org Chem. 2007 Jan 5;72(1):173-9. (PMID: 17194096)
Pharmacol Res. 2020 Feb;152:104609. (PMID: 31862477)
EMBO Mol Med. 2020 Aug 7;12(8):e11987. (PMID: 32672423)
J Am Chem Soc. 2016 Nov 2;138(43):14303-14311. (PMID: 27726344)
Biochem J. 2008 Nov 1;415(3):353-65. (PMID: 18588507)
Bioorg Med Chem. 2015 Oct 1;23(19):6520-7. (PMID: 26358279)
Eur J Med Chem. 2014 May 6;78:217-24. (PMID: 24681986)
Bioorg Med Chem. 2017 Jul 1;25(13):3471-3482. (PMID: 28495381)
Nat Cell Biol. 2002 May;4(5):E127-30. (PMID: 11988757)
Nature. 2020 Jul;583(7816):459-468. (PMID: 32353859)
Cell Physiol Biochem. 2009;24(5-6):347-60. (PMID: 19910675)
Mol Plant. 2015 May;8(5):709-21. (PMID: 25744360)
Adv Enzyme Regul. 2008;48:179-87. (PMID: 18492491)
Biochem Biophys Res Commun. 2004 Sep 3;321(4):1040-4. (PMID: 15358133)
Biochim Biophys Acta. 2010 Mar;1804(3):440-4. (PMID: 19879387)
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):263-70. (PMID: 16198160)
فهرسة مساهمة: Keywords: ATP-site; CK2; COVID-19; cancer; inhibitor; kinase; molecular probe
المشرفين على المادة: 0 (Molecular Probes)
0 (Naphthyridines)
0 (Phenazines)
0 (Polyphenols)
0 (Protein Kinase Inhibitors)
53-85-0 (Dichlororibofuranosylbenzimidazole)
8L70Q75FXE (Adenosine Triphosphate)
C6RWP0N0L2 (silmitasertib)
EC 2.7.- (Protein Kinases)
EC 2.7.11.1 (Casein Kinase II)
تواريخ الأحداث: Date Created: 20210403 Date Completed: 20210412 Latest Revision: 20231111
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8037657
DOI: 10.3390/molecules26071977
PMID: 33807474
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules26071977